An observational study in Ulcerative Colitis (UC), sponsored by Pfizer. Active, not recruiting at 1 site in Japan. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Pfizer · Observational
A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice.
1,492 studies on the registry are indexed under Colitis, Ulcerative; 399 are open to participants now.
This study's enrollment of 1 is below the median of 157 across 395 observational studies indexed under Colitis, Ulcerative.
Browse Colitis, Ulcerative studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with moderate to severe ulcerative colitis for whom treatment with this drug was started for the first time after the contract date for this study.
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
Patients taking velsipity
Drug: Velsipity
2 milligrams(mg) tablet as provided in real world practice
Also known as: Etrasimod
The incidence of serious infections (adverse events and adverse drug reactions) and safety specifications (adverse drug reactions)
Time frame: Up to 52 weeks
Percentage of Participants With Symptomatic Remission
Time frame: 12 weeks and 52 weeks
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer